膀胱癌肿瘤免疫微环境中免疫抑制性细胞作用的研究进展
The Role of Immunosuppressive Cells in TME during the Progression of Bladder Cancer
DOI: 10.12677/jcpm.2025.41034, PDF,   
作者: 周浩彤, 施 琳*:内蒙古医科大学基础医学院病理教研室,内蒙古 呼和浩特
关键词: 膀胱癌肿瘤微环境免疫抑制性细胞Bladder Cancer Tumor Microenvironment Immunosuppressive Cells
摘要: 膀胱癌(Bladder Cancer, BC)是一种潜在的致死性泌尿系统恶性肿瘤,发病率高,复发率和转移率也很高。肌层浸润性膀胱癌的预后更差。最新研究表明,肿瘤微环境(Tumor Microenvironment, TME)在BC的发展过程中起着至关重要的作用。TME由肿瘤细胞、免疫细胞、基质细胞、血管和细胞外基质(Extracellular Matrix, ECM)组成。其中免疫抑制细胞通过多种机制对BC的发生和发展起重要的免疫抑制作用。目前对免疫抑制细胞在BC中的作用还缺乏全面了解。因此,我们总结了免疫抑制细胞在膀胱癌微环境中的作用,为膀胱癌患者提供可能的治疗策略。
Abstract: Bladder cancer (BC), a potentially fatal malignancy of the urinary system, is highly prevalent with high rates of recurrence and metastasis. Furthermore, when it progresses into the muscle-invasive stage, it then leads to poor prognosis. Recent studies have shown that the tumor microenvironment (TME) plays a critical role in the progression of BC. TME is composed of tumor cells, immune cells, stromal cells, blood vessels and extracellular matrix (ECM). Among all components in TME, there is a very distinct group of cells defined as immunosuppressive cells, which have immunosuppressive influence on the process of tumorigenesis and progression of BC through multiple mechanisms. In recent decades, there is increasing focus on the immunosuppressive cells. However, there lacks a comprehensive understanding of immunosuppressive cells in BC. Herein, we summarized the role of immunosuppressive cells within the bladder cancer microenvironment, providing therapeutical strategies to potentially benefit BC patients.
文章引用:周浩彤, 施琳. 膀胱癌肿瘤免疫微环境中免疫抑制性细胞作用的研究进展[J]. 临床个性化医学, 2025, 4(1): 217-224. https://doi.org/10.12677/jcpm.2025.41034

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Dobruch, J. and Oszczudłowski, M. (2021) Bladder Cancer: Current Challenges and Future Directions. Medicina, 57, Article No. 749. [Google Scholar] [CrossRef] [PubMed]
[3] Charlton, M.E., Adamo, M., Sun, L. and Deorah, S. (2014) Bladder Cancer Collaborative Stage Variables and Their Data Quality, Usage, and Clinical Implications: A Review of SEER Data, 2004‐2010. Cancer, 120, 3815-3825. [Google Scholar] [CrossRef] [PubMed]
[4] van Osch, F.H., Jochems, S.H., van Schooten, F., Bryan, R.T. and Zeegers, M.P. (2016) Quantified Relations between Exposure to Tobacco Smoking and Bladder Cancer Risk: A Meta-Analysis of 89 Observational Studies. International Journal of Epidemiology, 45, 857-870. [Google Scholar] [CrossRef] [PubMed]
[5] Johnson, S.B. and Yu, J.B. (2018) Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Current Oncology Reports, 20, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[6] Oswald, D., Pallauf, M., Herrmann, T.R.W., et al. (2022) Transurethral Resection of Bladder Tumors (TURBT). Urologe A, 61, 71-82.
[7] Oddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., et al. (2013) Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate-and High-Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-Third Dose versus Full Dose and 1 Year versus 3 Years of Maintenance. European Urology, 63, 462-472. [Google Scholar] [CrossRef] [PubMed]
[8] Okobi, T.J., Uhomoibhi, T.O., Akahara, D.E., Odoma, V.A., Sanusi, I.A., Okobi, O.E., et al. (2023) Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence. Cureus, 15, e40031. [Google Scholar] [CrossRef] [PubMed]
[9] 张兰兰, 李向敏, 樊再雯. 免疫检查点抑制剂耐药机制的研究进展[J]. 肿瘤防治研究, 2020, 47(8): 636-640.
[10] Chen, X., Chen, H., He, D., Cheng, Y., Zhu, Y., Xiao, M., et al. (2021) Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 12, Article ID: 672158. [Google Scholar] [CrossRef] [PubMed]
[11] Huang, M., Liu, L., Zhu, J., Jin, T., Chen, Y., Xu, L., et al. (2021) Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer. Frontiers in Cell and Developmental Biology, 9, Article ID: 723817. [Google Scholar] [CrossRef] [PubMed]
[12] Schneider, A.K., Chevalier, M.F. and Derré, L. (2019) The Multifaceted Immune Regulation of Bladder Cancer. Nature Reviews Urology, 16, 613-630. [Google Scholar] [CrossRef] [PubMed]
[13] Chiba, Y., Mizoguchi, I., Hasegawa, H., Ohashi, M., Orii, N., Nagai, T., et al. (2017) Regulation of Myelopoiesis by Proinflammatory Cytokines in Infectious Diseases. Cellular and Molecular Life Sciences, 75, 1363-1376. [Google Scholar] [CrossRef] [PubMed]
[14] Veglia, F., Perego, M. and Gabrilovich, D. (2018) Myeloid-Derived Suppressor Cells Coming of Age. Nature Immunology, 19, 108-119. [Google Scholar] [CrossRef] [PubMed]
[15] Zheng, Z., Zheng, X., Zhu, Y., Yao, Z., Zhao, W., Zhu, Y., et al. (2021) IL‐6 Promotes the Proliferation and Immunosuppressive Function of Myeloid‐Derived Suppressor Cells via the MAPK Signaling Pathway in Bladder Cancer. BioMed Research International, 2021, Article ID: 5535578. [Google Scholar] [CrossRef] [PubMed]
[16] Leblond, M.M., Zdimerova, H., Desponds, E. and Verdeil, G. (2021) Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. Cancers, 13, Article No. 4712. [Google Scholar] [CrossRef] [PubMed]
[17] Cassetta, L. and Pollard, J.W. (2018) Targeting Macrophages: Therapeutic Approaches in Cancer. Nature Reviews Drug Discovery, 17, 887-904. [Google Scholar] [CrossRef] [PubMed]
[18] Gu, L., Guo, H., Wu, L. and Yuan, J. (2023) Prognostic Analysis and Validation of LncRNAs in Bladder Cancer on the Basis of Neutrophil Extracellular Traps. The Journal of Gene Medicine, 25, e3525. [Google Scholar] [CrossRef] [PubMed]
[19] Liu, K., Zhao, K., Wang, L. and Sun, E. (2018) The Prognostic Values of Tumor-Infiltrating Neutrophils, Lymphocytes and Neutrophil/Lymphocyte Rates in Bladder Urothelial Cancer. PathologyResearch and Practice, 214, 1074-1080. [Google Scholar] [CrossRef] [PubMed]
[20] Ikarashi, D., Kitano, S., Tsuyukubo, T., Yamashita, M., Matsuura, T., Maekawa, S., et al. (2024) Pathological Complete Response to Neoadjuvant Chemotherapy May Improve Antitumor Immune Response via Reduction of Regulatory T Cells in Muscle-Invasive Bladder Cancer. Scientific Reports, 14, Article No. 1442. [Google Scholar] [CrossRef] [PubMed]
[21] Koyama, S. and Nishikawa, H. (2021) Mechanisms of Regulatory T Cell Infiltration in Tumors: Implications for Innovative Immune Precision Therapies. Journal for ImmunoTherapy of Cancer, 9, e002591. [Google Scholar] [CrossRef] [PubMed]
[22] Garris, C.S., Wong, J.L., Ravetch, J.V. and Knorr, D.A. (2021) Dendritic Cell Targeting with Fc-Enhanced CD40 Antibody Agonists Induces Durable Antitumor Immunity in Humanized Mouse Models of Bladder Cancer. Science Translational Medicine, 13, eabd1346. [Google Scholar] [CrossRef] [PubMed]
[23] Segura, J. (2020) Decoding the Heterogeneity of Human Dendritic Cell Subsets. Trends in Immunology, 41, 1062-1071.
[24] Katz, S.I., Parker, D. and Turk, J.L. (1974) B-Cell Suppression of Delayed Hypersensitivity Reactions. Nature, 251, 550-551. [Google Scholar] [CrossRef] [PubMed]
[25] Shang, J., Zha, H. and Sun, Y. (2020) Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer. Frontiers in Immunology, 11, Article ID: 582657. [Google Scholar] [CrossRef] [PubMed]
[26] Derakhshani, A., Vahidian, F., Alihasanzadeh, M., Mokhtarzadeh, A., Lotfi Nezhad, P. and Baradaran, B. (2019) Mast Cells: A Double-Edged Sword in Cancer. Immunology Letters, 209, 28-35. [Google Scholar] [CrossRef] [PubMed]
[27] Aponte-López, A. and Muñoz-Cruz, S. (2020) Mast Cells in the Tumor Microenvironment. In: Birbrair, A., Ed., Tumor Microenvironment: Hematopoietic CellsPart B, Springer International Publishing, 159-173. [Google Scholar] [CrossRef] [PubMed]
[28] Zeltz, C., Primac, I., Erusappan, P., Alam, J., Noel, A. and Gullberg, D. (2020) Cancer-Associated Fibroblasts in Desmoplastic Tumors: Emerging Role of Integrins. Seminars in Cancer Biology, 62, 166-181. [Google Scholar] [CrossRef] [PubMed]
[29] Du, Y., Cao, J., Jiang, X., Cai, X., Wang, B., Wang, Y., et al. (2021) Comprehensive Analysis of CXCL12 Expression Reveals the Significance of Inflammatory Fibroblasts in Bladder Cancer Carcinogenesis and Progression. Cancer Cell International, 21, Article No. 613. [Google Scholar] [CrossRef] [PubMed]
[30] Liu, B., Pan, S., Liu, J. and Kong, C. (2021) Cancer-Associated Fibroblasts and the Related Runt-Related Transcription Factor 2 (RUNX2) Promote Bladder Cancer Progression. Gene, 775, Article ID: 145451. [Google Scholar] [CrossRef] [PubMed]
[31] Frerichs, L.M., Frerichs, B., Petzsch, P., Köhrer, K., Windolf, J., Bittersohl, B., et al. (2023) Tumorigenic Effects of Human Mesenchymal Stromal Cells and Fibroblasts on Bladder Cancer Cells. Frontiers in Oncology, 13, Article ID: 1228185. [Google Scholar] [CrossRef] [PubMed]
[32] Liang, T., Tao, T., Wu, K., Liu, L., Xu, W., Zhou, D., et al. (2023) Cancer‐Associated Fibroblast‐Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer. Advanced Science, 10, e2303230. [Google Scholar] [CrossRef] [PubMed]
[33] Yang, M., Wang, B., Hou, W., Zeng, H., He, W., Zhang, X., et al. (2024) NAD+ Metabolism Enzyme NNMT in Cancer-Associated Fibroblasts Drives Tumor Progression and Resistance to Immunotherapy by Modulating Macrophages in Urothelial Bladder Cancer. Journal for ImmunoTherapy of Cancer, 12, e009281. [Google Scholar] [CrossRef] [PubMed]
[34] Morales-Barrera, R., Suárez, C., de Castro, A.M., Racca, F., Valverde, C., Maldonado, X., et al. (2016) Targeting Fibroblast Growth Factor Receptors and Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer: New Direction and New Hope. Cancer Treatment Reviews, 50, 208-216. [Google Scholar] [CrossRef] [PubMed]
[35] Wang, J., Li, D., Cang, H. and Guo, B. (2019) Crosstalk between Cancer and Immune Cells: Role of Tumor‐Associated Macrophages in the Tumor Microenvironment. Cancer Medicine, 8, 4709-4721. [Google Scholar] [CrossRef] [PubMed]
[36] 钱俊安, 张琳, 杨萌, 等. 免疫抑制细胞在膀胱癌TME中的免疫抑制作用机制及特异性治疗研究进展[J]. 山东医药, 2022, 62(24): 107-110.
[37] 苏峥, 任海朋, 依荷芭丽·迟. 调节性T细胞与肿瘤免疫治疗的研究进展[J]. 癌症进展, 2023, 21(8): 824-829+865.